The sample size was then increased to verify the above findings.Patients with lower ANGPTL3 expression in RCC tissues had a higher proportion of sorafenib resistance (Fig. 1e–g, Supplementary Table 2). Here, ANGPTL3 is linked to renal cell carcinoma.